As per the research conducted by KD Market research, the
report titled “ Cognitive and Memory Enhancer
Drugs Market ” provides current as well as future
analysis of the market by evaluating the major applications, advantages,
trends, and challenges. The report dives deeper to produce useful insights
into Cognitive and Memory Enhancer Drugs Market such as major global regions and key
competitors and strategies that can be used for the entry-level player too.
Cognitive enhancers are drugs and supplements, which are
majorly used by patients suffering from Alzheimer’s disease, schizophrenia,
stroke, attention deficit hyperactivity disorder, or aging. In addition, these
drugs are used by health individuals to improve cognitive functions such as
memory, intelligence, motivation, stamina, alertness attention, and
concentration.
Request for sample@ https://www.kdmarketresearch.com/sample/3459
The global cognitive and memory enhancer drugs market
was valued at $3,680 million in 2016, and is projected to reach $6,598 million
by 2023, growing at a CAGR of 8.6% from 2017 to 2023. The growth of the global cognitive
and memory enhancer drugs market is driven by surge in geriatric population
and rise in prevalence of neurological & memory-related disorders.
Furthermore, the benefits offered by cognitive drugs such as improved memory
and reasoning fuel the market growth. However, ethical issues related to the
use of these drugs impede the market growth.
The global cognitive and memory enhancer drugs market
is segmented on the basis of product, application, and region. Based on
product, the market is categorized into Aricept, Razadyne, Namenda, Exelon,
Provigil, Ritalin, Adderall, and others. The applications covered in the study
include disease treatment, academic performance, athletic performance, and
others. Disease treatment segment is further bifurcated into developmental
conditions and neurodegenerative disease. By region, the market is analyzed
across North America, Europe, Asia-Pacific, and LAMEA.
KEY BENEFITS FOR STAKEHOLDERS
– This report provides an extensive analysis of the current
and emerging trends and dynamics in the global cognitive and memory enhancer
drugs market.
– This study provides the competitive landscape of the global market to predict the competitive environment across geographies.
– This report entails the detailed quantitative analysis of the current trends and future estimations to identify the prevailing opportunities.
– Comprehensive analysis of factors that drive and restrict the market growth is provided in the report.
– Region- and country-wise analysis is provided to understand the market trends and dynamics.
KEY MARKET SEGMENTS
By Product
– Aricept
– Exelon
– Namenda
– Razadyne
– Provigil
– Ritalin
– Adderall
– Others
– Exelon
– Namenda
– Razadyne
– Provigil
– Ritalin
– Adderall
– Others
By Application
– Disease Treatment-
– – Developmental Conditions
– – Neurodegenerative Conditions
– Academic Performance
– Athletic Performance
– Others
By Region
– North America
– – U.S.
– – Canada
– – Mexico
– – U.S.
– – Canada
– – Mexico
– Europe
– – Germany
– – France
– – UK
– – Italy
– – Spain
– – Rest of Europe
– Asia-Pacific
– – Japan
– – China
– – India
– – Australia
– – Rest of Asia-Pacific
– LAMEA
– – Brazil
– – Saudi Arabia
– – South Africa
– – Rest of LAMEA
The key players profiled in this report are as follows:
– Pfizer Inc.
– Eisai Co., Ltd.
– Allergan, Inc.
– Novartis AG
– Shire
– Johnson & Johnson
– Takeda Pharmaceutical Company Limited
– AlternaScript LLC
– Cephalon, Inc. (Teva Pharmaceutical Industries Ltd.)
– Ceretropic
– Eisai Co., Ltd.
– Allergan, Inc.
– Novartis AG
– Shire
– Johnson & Johnson
– Takeda Pharmaceutical Company Limited
– AlternaScript LLC
– Cephalon, Inc. (Teva Pharmaceutical Industries Ltd.)
– Ceretropic
Browse full report with toc@ https://www.kdmarketresearch.com/report/3459/cognitive-and-memory-enhancer-drugs-market-amr
Table of
content
CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. KEY BENEFITS FOR STAKEHOLDERS
1.3. KEY MARKET SEGMENTS
1.2. KEY BENEFITS FOR STAKEHOLDERS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO perspective
2.2. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top winning strategies
3.2.1.1. Top winning strategies, by year, 2015-2018*
3.2.1.2. Top winning strategies, by development, 2015-2018* (%)
3.2.1.3. Top winning strategies, by company, 2015-2018*
3.2.1.2. Top winning strategies, by development, 2015-2018* (%)
3.2.1.3. Top winning strategies, by company, 2015-2018*
3.2.2. Top investment pockets
3.3. Market share analysis, 2016
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Rapidly aging population
3.4.1.2. High incidence of neurodegenerative disorders
3.4.1.3. Benefits of smart drugs
3.4.1.2. High incidence of neurodegenerative disorders
3.4.1.3. Benefits of smart drugs
3.4.2. Restraints
3.4.2.1. Ethical issues
3.4.3. Opportunities
3.4.3.1. Effective strength of the drugs
CHAPTER 4: COGNITIVE AND MEMORY ENHANCER DRUGS MARKET, BY
PRODUCT
4.1. Overview
4.1.1. Market size and forecast
4.2. Aricept
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis, by country
4.2.2. Market size and forecast, by region
4.2.3. Market analysis, by country
4.3. Exelon
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis, by country
4.3.2. Market size and forecast, by region
4.3.3. Market analysis, by country
4.4. Namenda
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market analysis, by country
4.4.2. Market size and forecast, by region
4.4.3. Market analysis, by country
4.5. Razadyne
4.5.1. Key market trends, growth factors and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market analysis, by country
4.5.2. Market size and forecast, by region
4.5.3. Market analysis, by country
4.6. Provigil
4.6.1. Key market trends, growth factors and opportunities
4.6.2. Market size and forecast, by region
4.6.3. Market analysis, by country
4.6.2. Market size and forecast, by region
4.6.3. Market analysis, by country
4.7. Ritalin
4.7.1. Key market trends, growth factors and opportunities
4.7.2. Market size and forecast, by region
4.7.3. Market analysis, by country
4.7.2. Market size and forecast, by region
4.7.3. Market analysis, by country
4.8. Adderall
4.8.1. Key market trends, growth factors and opportunities
4.8.2. Market size and forecast, by region
4.8.3. Market analysis, by country
4.8.2. Market size and forecast, by region
4.8.3. Market analysis, by country
4.9. Others
4.9.1. Key market trends, growth factors and opportunities
4.9.2. Market size and forecast, by region
4.9.3. Market analysis, by country
4.9.2. Market size and forecast, by region
4.9.3. Market analysis, by country
CHAPTER 5: COGNITIVE AND MEMORY ENHANCER DRUGS MARKET BY
APPLICATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Disease treatment
5.2.1. Market size and forecast by type
5.2.2. Developmental conditions
5.2.2.1. Market size and forecast
5.2.3. Neurodegenerative disorders
5.2.3.1. Market size and forecast
5.2.4. Market size and forecast, by region
5.2.5. Market analysis, by country
5.2.5. Market analysis, by country
5.3. Academic performance
5.3.1. Market size and forecast, by region
5.3.2. Market analysis, by country
5.3.2. Market analysis, by country
5.4. Athletic performance
5.4.1. Market size and forecast, by region
5.4.2. Market analysis, by country
5.4.2. Market analysis, by country
5.5. Others
5.5.1. Market size and forecast, by region
5.5.2. Market analysis, by country
5.5.2. Market analysis, by country
CHAPTER 6: COGNITIVE AND MEMORY ENHANCER DRUGS MARKET BY
REGION
6.1. Overview
6.1.1. Market size and forecast
6.2. North America
6.2.1. Key market trends, growth factors and opportunities
6.2.2. North America market size and forecast, by country
6.2.2.1. U.S. cognitive and memory enhancer drugs market
6.2.2.1.1. U.S. market size and forecast, by product
6.2.2.1.2. U.S. market size and forecast, by application
6.2.2.1.2. U.S. market size and forecast, by application
6.2.2.2. Canada cognitive and memory enhancer drugs
market
6.2.2.2.1. Canada market size and forecast, by product
6.2.2.2.2. Canada market size and forecast, by application
6.2.2.2.2. Canada market size and forecast, by application
6.2.2.3. Mexico cognitive and memory enhancer drugs
market
6.2.2.3.1. Mexico market size and forecast, by product
6.2.2.3.2. Mexico market size and forecast, by application
6.2.2.3.2. Mexico market size and forecast, by application
6.2.3. North America market size and forecast, by product
6.2.4. North America market size and forecast, by application
6.2.4. North America market size and forecast, by application
6.3. Europe
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by country
6.3.2. Market size and forecast, by country
6.3.2.1. Germany cognitive and memory enhancer drugs
market
6.3.2.1.1. Germany market size and forecast, by product
6.3.2.1.2. Germany market size and forecast, by application
6.3.2.1.2. Germany market size and forecast, by application
6.3.2.2. France cognitive and memory enhancer drugs
market
6.3.2.2.1. France market size and forecast, by product
6.3.2.2.2. France market size and forecast, by application
6.3.2.2.2. France market size and forecast, by application
6.3.2.3. UK cognitive and memory enhancer drugs market
6.3.2.3.1. UK market size and forecast, by product
6.3.2.3.2. UK market size and forecast, by application
6.3.2.3.2. UK market size and forecast, by application
6.3.2.4. Italy cognitive and memory enhancer drugs market
6.3.2.4.1. Italy market size and forecast, by product
6.3.2.4.2. Italy market size and forecast, by application
6.3.2.4.2. Italy market size and forecast, by application
6.3.2.5. Spain cognitive and memory enhancer drugs market
6.3.2.5.1. Spain market size and forecast, by product
6.3.2.5.2. Spain market size and forecast, by application
6.3.2.5.2. Spain market size and forecast, by application
6.3.2.6. Rest of Europe cognitive and memory enhancer
drugs market
6.3.2.6.1. Rest of Europe market size and forecast, by
product
6.3.2.6.2. Rest of Europe market size and forecast, by application
6.3.2.6.2. Rest of Europe market size and forecast, by application
6.3.3. Europe market size and forecast, by product
6.3.4. Europe market size and forecast, by application
6.3.4. Europe market size and forecast, by application
6.4. Asia-Pacific
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by country
6.4.2. Market size and forecast, by country
6.4.2.1. Japan cognitive and memory enhancer drugs market
6.4.2.1.1. Japan market size and forecast, by product
6.4.2.1.2. Japan market size and forecast, by application
6.4.2.1.2. Japan market size and forecast, by application
6.4.2.2. China cognitive and memory enhancer drugs market
6.4.2.2.1. China market size and forecast, by product
6.4.2.2.2. China market size and forecast, by application
6.4.2.2.2. China market size and forecast, by application
6.4.2.3. India cognitive and memory enhancer drugs market
6.4.2.3.1. India market size and forecast, by product
6.4.2.3.2. India market size and forecast, by application
6.4.2.3.2. India market size and forecast, by application
6.4.2.4. Australia cognitive and memory enhancer drugs
market
6.4.2.4.1. Australia market size and forecast, by product
6.4.2.4.2. Australia market size and forecast, by application
6.4.2.4.2. Australia market size and forecast, by application
6.4.2.5. Rest of Asia-Pacific cognitive and memory
enhancer drugs market
6.4.2.5.1. Rest of Asia-Pacific market size and forecast, by
product
6.4.2.5.2. Rest of Asia-Pacific market size and forecast, by application
6.4.2.5.2. Rest of Asia-Pacific market size and forecast, by application
6.4.3. Asia-Pacific market size and forecast, by product
6.4.4. Asia-Pacific market size and forecast, by application
6.4.4. Asia-Pacific market size and forecast, by application
6.5. LAMEA
6.5.1. Key market trends, growth factors and opportunities
6.5.2. Market size and forecast by country
6.5.2. Market size and forecast by country
6.5.2.1. Brazil cognitive and memory enhancer drugs
market
6.5.2.1.1. Brazil market size and forecast, by product
6.5.2.1.2. Brazil market size and forecast, by application
6.5.2.1.2. Brazil market size and forecast, by application
6.5.2.2. Saudi Arabia cognitive and memory enhancer drugs
market
6.5.2.2.1. Saudi Arabia market size and forecast, by product
6.5.2.2.2. Saudi Arabia market size and forecast, by application
6.5.2.2.2. Saudi Arabia market size and forecast, by application
6.5.2.3. South Africa cognitive and memory enhancer drugs
market
6.5.2.3.1. South Africa market size and forecast, by product
6.5.2.3.2. South Africa market size and forecast, by application
6.5.2.3.2. South Africa market size and forecast, by application
6.5.2.4. Rest of LAMEA cognitive and memory enhancer
drugs market
6.5.2.4.1. Rest of LAMEA market size and forecast, by
product
6.5.2.4.2. Rest of LAMEA market size and forecast, by application
6.5.2.4.2. Rest of LAMEA market size and forecast, by application
6.5.3. LAMEA market size and forecast, by product
6.5.4. LAMEA market size and forecast, by application
6.5.4. LAMEA market size and forecast, by application
CHAPTER 7: COMPANY PROFILES
7.1. Allergan Plc.
7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Product portfolio
7.1.5. Business performance
7.1.6. Key strategic moves and developments
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Product portfolio
7.1.5. Business performance
7.1.6. Key strategic moves and developments
7.2. AlternaScript LLC
7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Product portfolio
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Product portfolio
7.3. Ceretropic
7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Product portfolio
7.3.2. Company snapshot
7.3.3. Product portfolio
7.4. Eisai Co. Ltd.
7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Product portfolio
7.4.5. Business performance
7.4.6. Key strategic moves and developments
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Product portfolio
7.4.5. Business performance
7.4.6. Key strategic moves and developments
7.5. Johnson & Johnson
7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Product portfolio
7.5.5. Business performance
7.5.6. Key strategic moves and developments
7.5.3. Operating business segments
7.5.4. Product portfolio
7.5.5. Business performance
7.5.6. Key strategic moves and developments
7.6. Novartis International AG
7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Product portfolio
7.6.5. Business performance
7.6.6. Key strategic moves and developments
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Product portfolio
7.6.5. Business performance
7.6.6. Key strategic moves and developments
7.7. Pfizer Inc.
7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Product portfolio
7.7.5. Business performance
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Product portfolio
7.7.5. Business performance
7.8. Shire Plc.
7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Product portfolio
7.8.5. Business performance
7.8.6. Key strategic moves and developments
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Product portfolio
7.8.5. Business performance
7.8.6. Key strategic moves and developments
7.9. Takeda Pharmaceutical Company Ltd.
7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Product portfolio
7.9.5. Business performance
7.9.6. Key strategic moves and developments
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Product portfolio
7.9.5. Business performance
7.9.6. Key strategic moves and developments
7.10. Teva Pharmaceutical Industries Ltd. (Cephalon Inc.)
About Us:
KD Market Research is one of the best market research
organization that provides B2B research on the growth opportunities of the
industry which is the prime factor of the overall revenue of the organization.
We identify the pain points which our client is facing around revenue methods
and provide them with a comprehensive database which helps them to make
intelligent decisions that could ensure growth to the organization.
Our Services include market intelligence, competitive
intelligence, and customized research. These research reports help the
organizations to make quick and powerful decisions that make out highest growth
in revenue.
Contact
us - KD Market
Research
150 State Street, Albany,
New York, USA 12207
No comments:
Post a Comment